Skip to main content
Figure 3 | Journal of Hematology & Oncology

Figure 3

From: A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Figure 3

Comparison of complete remission (CR) rates of CAG regimen in new, refractory and relapsed AML patients--Forest plot of CR event rates. Summary CR rates of CAG regimen were calculated using the random-effects model. Horizontal lines through the squares represent 95% confidence interval (CI). The diamonds represent the overall CR event rate from the meta-analyses and the corresponding 95% CIs. The studies that enrolled both new and relapsed/refractory AML were separated into two groups for this analysis, indicated by "-A". CAG: cytarabine, aclarubicin and G-CSF.

Back to article page